Olmesartan prevents cardiac rupture in mice with myocardial infarction by modulating growth differentiation factor 15 and p53

British Journal of Pharmacology

Volumn 171, Issue 15, 2014, Pages 3741-3753

  Chen, Baihe ^a   Lu, Di ^a   Fu, Yujuan ^a   Zhang, Jingwen ^a   Huang, Xiaobo ^a   Cao, Shiping ^a   Xu, Dingli ^a   Bin, Jianping ^a   Kitakaze, Masafumi ^a,b   Huang, Qiaobing ^c   Liao, Yulin ^a  

^a FIRST MILITARY MEDICAL UNIVERSITY   (China)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

aldosterone; cardiac rupture; GDF 15; myocardial infarction; olmesartan; p53

Indexed keywords

ALDOSTERONE; CASPASE 3; GROWTH DIFFERENTIATION FACTOR 15; MYELOPEROXIDASE; OLMESARTAN; PROTEIN P53; TRANSCRIPTION FACTOR RUNX2; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; GDF15 PROTEIN, MOUSE; IMIDAZOLE DERIVATIVE; PEROXIDASE; TETRAZOLE DERIVATIVE;

ACUTE HEART FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; FIBROBLAST; FIBROBLAST CULTURE; GENE EXPRESSION; HEART CELL CULTURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART MUSCLE CELL; HEART RUPTURE; INCIDENCE; MALE; MORTALITY; MOUSE; NEWBORN; NICK END LABELING; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; STAINING; SURVIVAL RATE; UPREGULATION; WALL STRESS; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CELL CULTURE; DRUG EFFECTS; HYPOXIA; METABOLISM; MYOCARDIAL INFARCTION;

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; APOPTOSIS; CELLS, CULTURED; FIBROBLASTS; GROWTH DIFFERENTIATION FACTOR 15; HEART RUPTURE; HYPOXIA; IMIDAZOLES; MALE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; PEROXIDASE; TETRAZOLES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84904559054     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12736     Document Type: Article

References (31)

1. Abadir PM, Walston JD, Carey RM, Siragy HM, (2011). Angiotensin II type-2 receptors modulate inflammation through signal transducer and activator of transcription proteins 3 phosphorylation and TNFalpha production. J Interferon Cytokine Res 31: 471-474.
2. Acosta E, Pena O, Naftolin F, Avila J, Palumbo A, (2009). Angiotensin II induces apoptosis in human mural granulosa-lutein cells, but not in cumulus cells. Fertil Steril 91 (5 Suppl.): 1984-1989.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
4. Askari AT, Brennan ML, Zhou X, Drinko J, Morehead A, Thomas JD, etal. (2003). Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 197: 615-624.
5. Becker RC, Gore JM, Lambrew C, Weaver WD, Rubison RM, French WJ, etal. (1996). A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction. J Am Coll Cardiol 27: 1321-1326.
6. De Silva DS, Wilson RM, Hutchinson C, Ip PC, Garcia AG, Lancel S, etal. (2009). Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms. Am J Physiol Heart Circ Physiol 296: H1983-H1993.
7. Duerrschmid C, Crawford JR, Reineke E, Taffet GE, Trial J, Entman ML, etal. (2013). TNF receptor 1 signaling is critically involved in mediating angiotensin-II-induced cardiac fibrosis. J Mol Cell Cardiol 57: 59-67.
8. Fairlie WD, Moore AG, Bauskin AR, Russell PK, Zhang HP, Breit SN, (1999). MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation. J Leukoc Biol 65: 2-5.
9. Fliser D, Buchholz K, Haller H,; EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators (2004). Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110: 1103-1107.
10. Gao XM, White DA, Dart AM, Du XJ, (2012). Post-infarct cardiac rupture: recent insights on pathogenesis and therapeutic interventions. Pharmacol Ther 134: 156-179.
11. He BJ, Joiner ML, Singh MV, Luczak ED, Swaminathan PD, Koval OM, etal. (2011). Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat Med 17: 1610-1618.
12. Ichihara S, Senbonmatsu T, Price E Jr, Ichiki T, Gaffney FA, Inagami T, (2002). Targeted deletion of angiotensin II type 2 receptor caused cardiac rupture after acute myocardial infarction. Circulation 106: 2244-2249.
13. Iwamoto M, Hirohata S, Ogawa H, Ohtsuki T, Shinohata R, Miyoshi T, etal. (2010). Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan. Hypertens Res 33: 1305-1311.
14. Kanamori H, Takemura G, Li Y, Okada H, Maruyama R, Aoyama T, etal. (2007). Inhibition of Fas-associated apoptosis in granulation tissue cells accompanies attenuation of postinfarction left ventricular remodeling by olmesartan. Am J Physiol Heart Circ Physiol 292: H2184-H2194.
15. Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J, etal. (2011). GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 17: 581-588.
16. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
17. Leri A, Claudio PP, Li Q, Wang X, Reiss K, Wang S, etal. (1998). Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest 101: 1326-1342.
18. Li J, Yang L, Qin W, Zhang G, Yuan J, Wang F, (2013). Adaptive induction of growth differentiation factor 15 attenuates endothelial cell apoptosis in response to high glucose stimulus. PLoS ONE 8: e65549.
19. Lopez-Sendon J, Gurfinkel EP, Lopez de Sa E, Agnelli G, Gore JM, Steg PG, etal. (2010). Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. Eur Heart J 31: 1449-1456.
20. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
21. Matsusaka H, Ide T, Matsushima S, Ikeuchi M, Kubota T, Sunagawa K, etal. (2006). Targeted deletion of p53 prevents cardiac rupture after myocardial infarction in mice. Cardiovasc Res 70: 457-465.
22. Sandmann S, Li J, Fritzenkotter C, Spormann J, Tiede K, Fischer JW, etal. (2006). Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats. Blood Press 15: 116-128.
23. Savarese G, Costanzo P, Cleland JG, Vassallo E, Ruggiero D, Rosano G, etal. (2013). A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol 61: 131-142.
24. Shamshad F, Kenchaiah S, Finn PV, Soler-Soler J, McMurray JJ, Velazquez EJ, etal. (2010). Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). Am Heart J 160: 145-151.
25. Shibasaki Y, Nishiue T, Masaki H, Tamura K, Matsumoto N, Mori Y, etal. (2005). Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertens Res 28: 787-795.
26. Shimazaki M, Nakamura K, Kii I, Kashima T, Amizuka N, Li M, etal. (2008). Periostin is essential for cardiac healing after acute myocardial infarction. J Exp Med 205: 295-303.
27. Sun Y, (2010). Intracardiac renin-angiotensin system and myocardial repair/remodeling following infarction. J Mol Cell Cardiol 48: 483-489.
28. Westermann D, Becher PM, Lindner D, Savvatis K, Xia Y, Frohlich M, etal. (2012). Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. Basic Res Cardiol 107: 308-320.
29. Xuan W, Wu B, Chen C, Chen B, Zhang W, Xu D, etal. (2012). Resveratrol improves myocardial ischemia and ischemic heart failure in mice by antagonizing the detrimental effects of fractalkine. Crit Care Med 40: 3026-3033.
30. Zhao Q, Ishibashi M, Hiasa K, Tan C, Takeshita A, Egashira K, (2004). Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension 44: 264-270.
31. Zidar N, Jeruc J, Balazic J, Stajer D, (2005). Neutrophils in human myocardial infarction with rupture of the free wall. Cardiovasc Pathol 14: 247-250.